Three years ago, Merck & Co. Inc. could not be more optimistic about the future of biosimilars.
At a time when many large pharmaceutical companies were still fighting the idea of “generic” versions of large molecules, Merck...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?